The DuPont Human Microbiome Venture has announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of next generation probiotics for human health.
In order to accelerate development and commercialisation, both companies are joining forces to develop the probiotics, initially to be used in dietary supplements.
Studies have shown diet and poor lifestyle choices negatively affect the gut microbiota which can result in chronic low-grade inflammation which, in turn, is closely associated with the onset and prevalence of metabolic health related conditions.
On the contrary, increasing levels of certain anaerobic bacteria in the gut has been shown to increase insulin sensitivity and thus helps to maintain healthy blood sugar levels.
“It’s an exciting opportunity to partner with P&G to jointly develop the next generation of microbe-based products. The combination of DuPont’s and P&G’s unique set of capabilities will allow us to accelerate innovation in the field of metabolic health and help millions of consumers affected by metabolic health issues,” said Sebastien Guery, Human Microbiome Venture leader, DuPont Nutrition & Biosciences.
“As a company focused on innovation, P&G is excited to come together with our valued partners at DuPont.” said Paul Gama, president, P&G Personal Health Care.
